Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted radiopharmaceutical therapy with cessation of castration. Half of patients are randomized to either receive, or not receiv

Trial Details

NCT ID
NCT06084338
Phase
PHASE2
Sponsor
VA Office of Research and Development
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • stereotactic ablative radiotherapy
  • Pluvicto
  • topical testosterone
Locations (sample)
  • West Los Angeles, California, United States|34.0462,-118.43068
  • Hines, Illinois, United States|41.85364,-87.8395
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

  • Subject must be 18 years of age or older at the time the Informed Consent is signed
  • The subject (or legally acceptable representative if applicable) must provide written informed consent for the trial
  • Pathologic diagnosis of prostate cancer of adenocarcinoma histology; presence small cell/neuroendocrine carcinoma is exclusionary
  • Metastatic disease as documented by:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →